Literature DB >> 16123085

Mullerian inhibiting substance levels at the time of HCG administration in IVF cycles predict both ovarian reserve and embryo morphology.

T Silberstein1, D T MacLaughlin, I Shai, J R Trimarchi, G Lambert-Messerlian, D B Seifer, D L Keefe, A S Blazar.   

Abstract

BACKGROUND: Pre-antral and early antral follicles secrete Müllerian inhibiting substance (MIS), suggesting that MIS may directly reflect ovarian reserve. Since little is known about how ovarian reserve affects oocyte quality, we attempt here to assess the predictive value of MIS on embryo morphology and IVF outcome. To do so, we measured MIS at the time of HCG administration 36 h prior to oocyte retrieval.
METHODS: A total of 257 patients undergoing IVF were prospectively recruited. We measured MIS levels by enzyme-linked immunosorbent assay at the time of HCG, and compared the MIS values to day 3 FSH levels in the prediction of embryo morphology and IVF outcome.
RESULTS: The distribution of MIS levels was skewed, with a median of 2.7 ng/ml (range 0 to 28.5 ng/ml). MIS values at the time of HCG administration inversely correlated with basal FSH levels (P = 0.002), and both correlated significantly with patient age, number of mature follicles, number of oocytes retrieved and serum estradiol levels. MIS levels correlated significantly with a greater number of 6-cell embryos and better embryo morphology score, while basal FSH levels did not correlate with these outcome variables. MIS levels > or =2.7 ng/ml portended improved oocyte quality as reflected in a higher implantation rate (P = 0.001) and a trend toward a better clinical pregnancy rate (P = 0.084).
CONCLUSIONS: MIS levels seem to predict not only ovarian reserve, but also embryo morphology. Measurement of MIS at the time of HCG administration may, therefore, in the future improve management of patients undergoing treatments with assisted reproductive technology.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16123085     DOI: 10.1093/humrep/dei270

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  49 in total

Review 1.  Ovarian reserve evaluation: state of the art.

Authors:  Bruno Ramalho de Carvalho; Ana Carolina Japur de Sá Rosa e Silva; Júlio César Rosa e Silva; Rosana Maria dos Reis; Rui Alberto Ferriani; Marcos Felipe Silva de Sá
Journal:  J Assist Reprod Genet       Date:  2008-08-05       Impact factor: 3.412

2.  Effect of Anti-Müllerian hormone (AMH) and bone morphogenetic protein 15 (BMP-15) on steroidogenesis in primary-cultured human luteinizing granulosa cells through Smad5 signalling.

Authors:  Ermioni Prapa; Anna Vasilaki; Konstantinos Dafopoulos; Eleni Katsiani; Panagiotis Georgoulias; Christina I Messini; George Anifandis; Ioannis E Messinis
Journal:  J Assist Reprod Genet       Date:  2015-05-24       Impact factor: 3.412

Review 3.  Premature ovarian insufficiency: from pathogenesis to clinical management.

Authors:  S Luisi; C Orlandini; C Regini; A Pizzo; F Vellucci; F Petraglia
Journal:  J Endocrinol Invest       Date:  2015-01-18       Impact factor: 4.256

4.  Anti-mullerian hormone as a predictive marker for the selection of women for oocyte in vitro maturation treatment.

Authors:  Rubens Fadini; Ruggero Comi; Mario Mignini Renzini; Giovanni Coticchio; Marilena Crippa; Elena De Ponti; Mariabeatrice Dal Canto
Journal:  J Assist Reprod Genet       Date:  2011-06-15       Impact factor: 3.412

5.  Correlation of serum Anti-Müllerian hormone concentrations on day 3 of the in vitro fertilization stimulation cycle with assisted reproduction outcome in polycystic ovary syndrome patients.

Authors:  Wenyan Xi; Fei Gong; Guangxiu Lu
Journal:  J Assist Reprod Genet       Date:  2012-03-02       Impact factor: 3.412

6.  Anti-Mullerian hormone and antral follicle count as predictors for embryo/oocyte cryopreservation cycle outcomes in breast cancer patients stimulated with letrozole and follicle stimulating hormone.

Authors:  Sanghoon Lee; Sinan Ozkavukcu; Elke Heytens; Fred Moy; Rose M Alappat; Kutluk Oktay
Journal:  J Assist Reprod Genet       Date:  2011-05-04       Impact factor: 3.412

7.  Low estradiol responses in oocyte donors undergoing gonadotropin stimulation do not influence clinical outcomes.

Authors:  Katherine L Palmerola; Briana J Rudick; Rogerio A Lobo
Journal:  J Assist Reprod Genet       Date:  2018-04-27       Impact factor: 3.412

8.  Anti-Müllerian hormone (AMH): a reliable biomarker of oocyte quality in IVF.

Authors:  Pierre Lehmann; Maria P Vélez; Julio Saumet; Louise Lapensée; Wael Jamal; François Bissonnette; Simon Phillips; Isaac-Jacques Kadoch
Journal:  J Assist Reprod Genet       Date:  2014-02-27       Impact factor: 3.412

9.  Serum anti-Müllerian hormone predicts ovarian response and cycle outcome in IVF patients.

Authors:  Cheng-Hsuan Wu; Yu-Ching Chen; Hsin-Hung Wu; Jyuer-Ger Yang; Yu-Jun Chang; Horng-Der Tsai
Journal:  J Assist Reprod Genet       Date:  2009-07       Impact factor: 3.412

10.  Impact of female age and male infertility on ovarian reserve markers to predict outcome of assisted reproduction technology cycles.

Authors:  Tsung-Hsien Lee; Chung-Hsien Liu; Chun-Chia Huang; Kung-Chen Hsieh; Pi-Mei Lin; Maw-Sheng Lee
Journal:  Reprod Biol Endocrinol       Date:  2009-09-17       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.